You did everything right. You picked an eating window. You white-knuckled through the morning hunger. You watched the clock hit noon like it was Christmas morning, and then you ate your sensible lunch and felt virtuous about it.
And it worked. For a while.
Then the scale stopped moving. Then it crept back up. And you blamed yourself, because that is what women do when a diet fails — we assume the problem is us, not the diet.
It wasn’t you. A 2026 Cochrane systematic review just confirmed what your body already knew: intermittent fasting does not work any better than regular dieting for sustained weight loss. Twenty-two randomized controlled trials. Nearly 2,000 participants. The difference between intermittent fasting and standard dietary advice? A 0.33% reduction in body weight (Garegnani et al., 2026). That is not a rounding error. That IS a rounding error.
I want to walk you through why this happens — the actual biology of it — because understanding the mechanism is the difference between blaming yourself for the next ten years and finding something that actually works with your body instead of against it.
The Cochrane Numbers, Plain English
Cochrane reviews are the gold standard of medical evidence. They pool data from multiple randomized controlled trials and assess how confident we can be in the results. This one looked at every decent IF trial published between 2016 and 2024 — time-restricted eating, alternate-day fasting, the 5:2 method, all of it.
Here is what they found.
When researchers compared intermittent fasting to standard dietary advice (the kind your doctor gives you — eat less, move more, here’s a calorie target), fasting produced a mean difference of negative 0.33% body weight. The 95% confidence interval crossed zero (-0.92 to 0.26), which means statistically, we cannot even say it was better at all (Garegnani et al., 2026).
When they looked at whether people hit the clinically meaningful threshold of 5% body weight loss, the relative risk was 0.98. That is a flat line. No difference.
Now, IF did beat doing literally nothing — a 3.42% reduction compared to no dietary intervention. But “better than nothing” is a low bar. Your morning coffee is better than nothing. That does not make it a weight loss strategy.
All of this evidence was rated LOW to VERY LOW certainty. Meaning even these modest findings might be overstating the case.
Why Your Body Fought You
The way I would explain it if you were standing in my kitchen: your body does not care about your eating window. It cares about survival.
When you restrict calories — whether through fasting or any other method — your hypothalamus notices. It is the part of your brain that controls hunger, metabolic rate, and energy expenditure, and it has been keeping humans alive through famines for about 200,000 years. It is very good at its job.
Three things happen almost immediately when you start losing weight through caloric restriction.
First, your leptin drops. Leptin is the hormone that tells your brain you have enough fat stored and can stop being hungry. As you lose fat, leptin falls, and your brain interprets this as a crisis. Not a lifestyle choice. A crisis. It responds by cranking up hunger signals (Rosenbaum & Leibel, 2010).
Second, ghrelin spikes. Ghrelin is the “I’m starving” hormone. Research shows that ghrelin levels increase significantly during fasting periods, and — here is the part that really gets me — they do not fully normalize even after you eat. Your body keeps screaming for more food even when you have technically eaten enough (Cummings et al., 2001).
Third, your metabolic rate drops. The famous Biggest Loser study followed contestants six years after the show and found their metabolisms were burning roughly 500 fewer calories per day than expected for their body size (Fothergill et al., 2016). Six years. Their bodies never stopped trying to regain the weight.
This is what you were fighting every time you stared at the clock waiting for your eating window to open. Not weakness. Biochemistry.
Intermittent Fasting Is a Calorie Trick With Better Marketing
I need to be honest about something. Intermittent fasting was never a metabolic intervention. It was always a calorie restriction strategy wearing a lab coat.
The original appeal was that IF would trigger autophagy, improve insulin sensitivity, activate some special metabolic pathway that regular dieting could not. And some of that research exists — in mice, in short-term studies, in highly controlled settings that look nothing like your actual life.
But when Cochrane pooled the human RCT data, the metabolic magic disappeared. IF produced essentially the same results as standard calorie counting. Because for most people, a smaller eating window just means fewer total calories consumed. That is the whole trick. And your hypothalamus does not care whether those missing calories came from skipping breakfast or counting points in an app. It responds the same way: more hunger, less metabolism, more fat storage efficiency.
The Cochrane review found no meaningful difference in fasting glucose, blood pressure, or waist circumference between IF and standard diets. The metabolic benefits were not there in the pooled data.
A Completely Different Mechanism
Here is where the conversation shifts, and this is the part I wish more people understood.
GLP-1 receptor agonists — semaglutide being the most studied — do not work by restricting when or how much you eat through willpower. They work by changing the signals your brain receives about hunger and satiety at the hypothalamic level.
GLP-1 is a hormone your gut naturally produces after eating. It tells your brain two things: you are full, and you can slow down gastric emptying (which keeps you feeling full longer). In people carrying excess weight, this signaling system is often blunted. The signal gets sent but the volume is turned down.
Semaglutide turns the volume back up. It binds to GLP-1 receptors in the hypothalamus and activates the same fullness pathways that food is supposed to trigger — but more reliably and more consistently than your blunted natural signals can manage (Drucker, 2018).
This is not a willpower game. This is pharmacology working with the same system that intermittent fasting works against.
The STEP 1 trial showed 14.9% body weight reduction with semaglutide 2.4mg over 68 weeks (Wilding et al., 2021). STEP 5 showed 15.2% at two years with sustained treatment (Garvey et al., 2022). Compare that to the Cochrane IF number: 0.33%.
I am not cherry-picking. Those are the largest, most rigorous trials we have for each approach. One works with your biology. The other asks you to overpower it.
Why This Matters More for Women
Women make up 76% of GLP-1 prescriptions in the US, and there is a reason for that. Women’s metabolic adaptation to caloric restriction is, in many cases, more aggressive than men’s.
Estrogen and progesterone fluctuations throughout the menstrual cycle directly affect ghrelin and leptin sensitivity. Many women report that IF is tolerable for two weeks of their cycle and absolutely brutal for the other two. That is not a discipline problem. That is hormonal biology making fasting physiologically harder at certain points in the cycle (Hirschberg, 2012).
Perimenopause makes it worse. As estrogen declines, insulin sensitivity shifts, visceral fat accumulation increases, and the hypothalamic set point for body weight appears to drift upward. Asking a perimenopausal woman to lose weight through caloric restriction alone is asking her to fight her endocrine system with a food journal.
GLP-1 agonists bypass this entire problem. They do not care about your cycle. They do not get less effective during the luteal phase. They modulate appetite through a pathway that operates independently of estrogen and progesterone fluctuations.
The Access Problem
So if GLP-1 agonists are studied for effects on body weight and the data is this clear, why is everyone still talking about intermittent fasting?
Cost. Branded semaglutide runs $900 to $1,350 per month without insurance. About 8.5 million commercially insured Americans have zero coverage for GLP-1 weight management. When the FDA pulled compounded semaglutide off the market in early 2025, roughly 1.8 million patients lost access to their $150-400/month alternative overnight.
Intermittent fasting is free. That is its real selling point. Not metabolic magic. Not superior science. It costs nothing, so it gets recommended to people who cannot afford the intervention that actually has strong clinical data behind it.
The research peptide market exists because of this gap. Women who understand the science, who have read the trial data, who know that IF gave them a 0.33% result — they are looking for access to compounds that have been studied for meaningful effects on body weight. And they deserve quality sources.
If you are going to source research peptides, third-party purity testing is not optional..
What the Cochrane Review Actually Tells Us
I do not think intermittent fasting is harmful. For some people, a structured eating window simplifies their day and helps them eat a bit less without tracking calories. That is fine.
What I object to is the framing. IF has been sold as a metabolic breakthrough when 22 randomized trials show it performs no differently than basic dietary advice. Women who tried it and failed did not lack discipline. They were using a tool that the best available evidence says produces clinically insignificant results compared to standard approaches.
The question was never “can you skip breakfast hard enough?” The question is whether the intervention actually changes the biological drivers of weight regulation. For IF, the Cochrane data says no. For GLP-1 receptor agonists, the STEP trials say yes.
Different mechanisms. Different outcomes. And you were never the problem.
References
1. Garegnani, L.I., et al. (2026). Intermittent fasting for adults with overweight or obesity. Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.CD015610.pub2
2. Rosenbaum, M. & Leibel, R.L. (2010). Adaptive thermogenesis in humans. International Journal of Obesity, 34(S1), S47-S55. DOI: 10.1038/ijo.2010.184
3. Cummings, D.E., et al. (2001). A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes, 50(8), 1714-1719. DOI: 10.2337/diabetes.50.8.1714
4. Fothergill, E., et al. (2016). Persistent metabolic adaptation 6 years after “The Biggest Loser” competition. Obesity, 24(8), 1612-1619. DOI: 10.1002/oby.21538
5. Drucker, D.J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740-756. DOI: 10.1016/j.cmet.2018.03.001
6. Wilding, J.P.H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. DOI: 10.1056/NEJMoa2032183
7. Garvey, W.T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity. Nature Medicine, 28, 2083-2091. DOI: 10.1038/s41591-022-02026-4
8. Hirschberg, A.L. (2012). Sex hormones, appetite and eating behaviour in women. Maturitas, 71(3), 248-256. DOI: 10.1016/j.maturitas.2011.12.016